Jennifer Chan, MD, MPH

Dr. Chan on Trial of Cabozantinib in Neuroendocrine Tumors

November 16th 2017

Jennifer Chan, MD, MPH, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses a trial of cabozantinib (Cabometyx) in neuroendocrine tumors (NETs).